Abstract
Inorganic arsenic (iAs) and its high toxic metabolite, monomethylarsonous acid (MMAIII), are able to induce malignant transformation of human cells. Chronic exposure to these chemicals is associated with an increased risk of developing multiple cancers in human. However, the mechanisms contributing to iAs/MMAIII-induced cell malignant transformation and carcinogenesis are not fully elucidated. We recently showed that iAs/MMAIII exposure to human cells led to a decreased level of histone acetylation globally, which was associated with an increased sensitivity to arsenic cytotoxicity. In the current study, it demonstrated that prolonged exposure to low-level MMAIII in human urothelial cells significantly increased the expression and activity of histone deacetylases (HDACs) with an associated reduction of histone acetylation levels both globally and lysine specifically. Administration of the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), at 4 weeks after the initial MMAIII treatment inhibited the MMAIII-mediated up-regulation of the expression and activities of HDACs, leading to increase histone acetylation and prevention of MMAIII-induced malignant transformation. These new findings suggest that histone acetylation dysregulation may be a key mechanism in MMAIII-induced malignant transformation and carcinogenesis, and that HDAC inhibitors could be targeted to prevent or treat iAs-related cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.